Perceptive Discovery, a global leader in molecular and functional imaging research, today announced the launch of the FIBRE (Fibrosis Imaging Biomarker R...
Results from the fixed-dose QWINT-1 study, along with the QWINT-3 and QWINT-4 studies, reinforce efsitora's potential to simplify insulin management with...
Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology ...
The BIO International Convention 2025 concluded in Boston with an exceptional display of biopharmaceutical innovation, regulatory dialogue, investment di...
GE HealthCare and the Department of Radiology at Stanford Medicine aim to explore total body positron emission tomography/computed tomography (PET/CT...
Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on devel...
Ecolab Life Sciences announced it has launched an innovative new resin to help achieve cost savings and optimize operations throughout the antibody manuf...
AI meets genomics in BioAro’s latest launch, unlocking faster, scalable drug discovery.PanOmiQ™ Research sets a new global benchmark for prec...
Integrated DNA Technologies (IDT), a global genomics leader, is expanding its infectious disease portfolio with new solutions to enhance worldwide research...
Expands the collaboration to manufacture two malaria vaccine candidates (R78C and RH5.1) for Phase 1/2 clinical trials. Delivers the sixth m...
Enzene, a pioneer in fully-connected continuous biologics manufacturing technology, announced that ahead of the official opening of its biologics manufactu...
ADCs are no longer a niche modality. To date, there are over a dozen approved ADCs on the market, and more than 500 programs are in clinical development, d...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today provided a safety update regarding ELEVIDYS (...
Genmab A/S announced new results from the Phase 1b/2 EPCORE® NHL-2 trial Arm 10 (NCT04663347), evaluating epcoritamab, a T-cell engaging bispeci...
© 2025 Biopharma Boardroom. All Rights Reserved.
